 Our business
AstraZeneca at a glance
We are a global, innovation-driven 
biopharmaceutical business. 
Our primary focus is the discovery, development and 
commercialisation of prescription medicines for six 
important areas of healthcare: Cardiovascular, 
Gastrointestinal, Infection, Neuroscience, Oncology,  
and Respiratory & Inflammation. We operate in over  
100 countries and our innovative medicines are used  
by millions of patients worldwide.
We want AstraZeneca to be valued as a source of great 
medicines and trusted as a company that delivers business 
success responsibly. Our Responsible Business Plan 
provides the framework for ensuring that we operate with 
integrity and high ethical standards across all our activities.
Brilinta/Brilique has 
been approved in 64 
countries; it has been 
launched in 37 countries 
and remains under 
review in 39 countries.
Regional sales  
Western Europe 
$8,501m
(-11%)
Around 32,300 
Sales and Marketing employees: numbers in 
Established Markets, such as the US, have fallen, 
whereas the numbers in Emerging Markets are 
increasing and now represent 47% of the total.
Regional sales  
Emerging Markets 
$5,763m
(+10%)
Around 57,200 
employees worldwide
Americas: 17,450 (31%)
EMEA: 26,600 (46%)
Asia-Pacific: 13,150 (23%)
Regional sales  
US 
$13,426m
(-2%) 
Launch of our new Global 
External Interactions  
Policy reinforces our 
commitment to the highest 
standards of sales and 
marketing practice.
Russia: We invested $150 million 
in a manufacturing plant near 
Moscow and announced plans 
to establish a new predictive 
science centre in St Petersburg.
AstraZeneca Annual Report and Form 20-F Information 2011 2 AstraZeneca at a glance Our top 10 medicines by sales value 
in 2011 were:
Cardiovascular
Crestor
for managing cholesterol levels 
Seloken/
Toprol-XL
for hypertension, heart failure  
and angina
Atacand 
for hypertension and heart failure
Gastrointestinal
Nexium
for acid-reflux
Losec/Prilosec 
for the treatment of acid related 
diseases
Infection
Synagis
for RSV, a respiratory infection  
in infants
Neuroscience
Seroquel IR
for schizophrenia and bipolar 
disorder
Seroquel XR 
for schizophrenia, bipolar disorder 
and major depressive disorder
Oncology
Zoladex 
for prostate and breast cancer
Respiratory & Inflammation
Symbicort
for asthma and chronic 
obstructive pulmonary disease
Around 1 1,300
employees work in our R&D organisation 
and we have 14 principal R&D centres  
in eight countries.
Our activities touch many people’s lives 
and we are committed to working in a 
spirit of collaboration to achieve our 
goal of better health for patients:
>  For patients and physicians, we provide medicines for 
some of the world’s most serious diseases.
>  For the people who pay for healthcare, we work to make 
sure that our medicines offer real value for money.
>  For our employees, we provide a culture in which  
they can feel appreciated, energised and rewarded  
for their contribution.
>  For our shareholders, we aim to deliver value through  
our continued focus on innovation and running our 
business efficiently.
>  For the wider community, we want to be valued for the 
contribution our medicines make to society and trusted  
for the way in which we do business.
We work closely with all our stakeholders to understand 
their challenges and how we can combine our skills and 
resources to achieve a common goal: improved health.
Around 9,600 
employees work at our 23 Supply and 
Manufacturing sites in 16 countries.
Regional sales  
Established ROW 
$5,901m
(+4%)
China: We announced  
our decision to invest  
$200 million in a 
manufacturing facility in 
Taizhou, Jiangsu province 
and our agreement to 
acquire Guangdong 
BeiKang Pharmaceutical 
Company Limited.
Overview
AstraZeneca Annual Report and Form 20-F Information 2011 AstraZeneca at a glance 3
